Ravikiran M. Raju

Ravikiran M. Raju

Auto-generated profile, based on publicly available information

Ravikiran M. Raju

Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2016 in Nature Medicine
Verified
Journal Article
Open access
PDF file
MMMohlopheni J Marakalala
Mohlopheni J Marakalala
RRRavikiran M Raju
Ravikiran M Raju
KSKirti Sharma
Kirti Sharma
YZYanjia J Zhang
Yanjia J Zhang
EEEliseo A Eugenin
Eliseo A Eugenin
EREric J Rubin
Eric J Rubin
Using proteomic analyses, Eric Rubin, Véronique Dartois and colleagues show that tuberculosis granulomas have spatially segregated protein compositions that compartmentalize pro- and anti-inflammatory responses to distinct regions. Granulomas are the pathological hallmark of tuberculosis (TB). However, their function and mechanisms of formation remain poorly understood. To understand the role of granulomas in TB, we analyzed the proteomes of granulomas from subjects with tuberculosis in an unbiased manner. Using laser-capture microdissection, mass spectrometry and confocal microscopy, we generated detailed molecular maps of human granulomas. We found that the centers of granulomas have a pro-inflammatory environment that is characterized by the presence of antimicrobial peptides, reactive oxygen species and pro-inflammatory eicosanoids. Conversely, the tissue surrounding the caseum has a comparatively anti-inflammatory signature. These findings are consistent across a set of six human subjects and in rabbits. Although the balance between systemic pro- and anti-inflammatory signals is crucial to TB disease outcome, here we find that these signals are physically segregated within each granuloma. From the protein and lipid snapshots of human and rabbit lesions analyzed here, we hypothesize that the pathologic response to TB is shaped by the precise anatomical localization of these inflammatory pathways during the development of the granuloma.

16 February 2012 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
RRRavikiran M. Raju
Ravikiran M. Raju
MUMeera Unnikrishnan
Meera Unnikrishnan
DRDaniel H. F. Rubin
Daniel H. F. Rubin
VKVidhya Krishnamoorthy
Vidhya Krishnamoorthy
OKOlga Kandror
Olga Kandror
EREric J. Rubin
Eric J. Rubin
In most bacteria, Clp protease is a conserved, non-essential serine protease that regulates the response to various stresses. Mycobacteria, including Mycobacterium tuberculosis (Mtb) and Mycobacterium smegmatis, unlike most well studied prokaryotes, encode two ClpP homologs, ClpP1 and ClpP2, in a single operon. Here we demonstrate that the two proteins form a mixed complex (ClpP1P2) in mycobacteria. Using two different approaches, promoter replacement, and a novel system of inducible protein degradation, leading to inducible expression of clpP1 and clpP2, we demonstrate that both genes are essential for growth and that a marked depletion of either one results in rapid bacterial death. ClpP1P2 protease appears important in degrading missense and prematurely terminated peptides, as partial depletion of ClpP2 reduced growth specifically in the presence of antibiotics that increase errors in translation. We further show that the ClpP1P2 protease is required for the degradation of proteins tagged with the SsrA motif, a tag co-translationally added to incomplete protein products. Using active site mutants of ClpP1 and ClpP2, we show that the activity of each subunit is required for proteolysis, for normal growth of Mtb in vitro and during infection of mice. These observations suggest that the Clp protease plays an unusual and essential role in Mtb and may serve as an ideal target for antimycobacterial therapy. Due to the significant and rapid rise in multidrug resistant Mycobacterium tuberculosis (Mtb), there is an urgent need to validate novel drug targets for the treatment of tuberculosis. Here, we show that Clp protease is an ideal potential target. Mtb encodes two ClpP genes, ClpP1 and ClpP2, which associate together to form a single proteolytic complex, referred to as ClpP1P2. Both proteins are required for growth in vitro and in a mouse model of infection. Depletion of either protein results in rapid death of the bacteria. Interestingly, this is rare among bacteria, most of which have only one ClpP gene that is dispensable for normal growth. We also show that Clp protease plays an important quality control role by clearing abnormally produced proteins. As known antimycobacterial therapeutics increase errors in protein synthesis, inhibitors of ClpP1P2 protease in Mtb may prove synergistic with already existing agents.

1 January 2012 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
VRValentina La Rosa
Valentina La Rosa
GPGiovanna Poce
Giovanna Poce
JCJulio Ortiz Canseco
Julio Ortiz Canseco
SBSilvia Buroni
Silvia Buroni
MPMaria Rosalia Pasca
Maria Rosalia Pasca
EREdda De Rossi
Edda De Rossi
The 1,5-diarylpyrrole derivative BM212 was previously shown to be active against multidrug-resistant clinical isolates and Mycobacterium tuberculosis residing within macrophages as well as against Mycobacterium avium and other atypical mycobacteria. To determine its mechanism of action, we identified the cellular target. Spontaneous Mycobacterium smegmatis , Mycobacterium bovis BCG, and M. tuberculosis H37Rv mutants that were resistant to BM212 were isolated. By the screening of genomic libraries and by whole-genome sequencing, we found that all the characterized mutants showed mutations in the mmpL3 gene, allowing us to conclude that resistance to BM212 maps to the MmpL3 protein, a member of the MmpL ( m ycobacterial m embrane p rotein, l arge) family. Susceptibility was unaffected by the efflux pump inhibitors reserpine, carbonylcyanide m -chlorophenylhydrazone, and verapamil. Uptake/efflux experiments with [ 14 C]BM212 demonstrated that resistance is not driven by the efflux of BM212. Together, these data strongly suggest that the MmpL3 protein is the cellular target of BM212.

27 January 2012 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
TATatos Akopian
Tatos Akopian
OKOlga Kandror
Olga Kandror
RRRavikiran M Raju
Ravikiran M Raju
MUMeera Unnikrishnan
Meera Unnikrishnan
EREric J Rubin
Eric J Rubin
AGAlfred Goldberg
Alfred Goldberg
Mycobacterium tuberculosis (Mtb) contains two clpP genes, both of which are essential for viability. We expressed and purified Mtb ClpP1 and ClpP2 separately. Although each formed a tetradecameric structure and was processed, they lacked proteolytic activity. We could, however, reconstitute an active, mixed ClpP1P2 complex after identifying N‐blocked dipeptides that stimulate dramatically (>1000‐fold) ClpP1P2 activity against certain peptides and proteins. These activators function cooperatively to induce the dissociation of ClpP1 and ClpP2 tetradecamers into heptameric rings, which then re‐associate to form the active ClpP1P2 2‐ring mixed complex. No analogous small molecule‐induced enzyme activation mechanism involving dissociation and re‐association of multimeric rings has been described. ClpP1P2 possesses chymotrypsin and caspase‐like activities, and ClpP1 and ClpP2 differ in cleavage preferences. The regulatory ATPase ClpC1 was purified and shown to increase hydrolysis of proteins by ClpP1P2, but not peptides. ClpC1 did not activate ClpP1 or ClpP2 homotetradecamers and stimulated ClpP1P2 only when both ATP and a dipeptide activator were present. ClpP1P2 activity, its unusual activation mechanism and ClpC1 ATPase represent attractive drug targets to combat tuberculosis.

1 October 2012 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
RRRavikiran M. Raju
Ravikiran M. Raju
AGAlfred L. Goldberg
Alfred L. Goldberg
EREric J. Rubin
Eric J. Rubin

3 November 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
SBScarlett J. Barker
Scarlett J. Barker
RRRavikiran M. Raju
Ravikiran M. Raju
NMNoah E.P. Milman
Noah E.P. Milman
JWJun Wang
Jun Wang
JDJose Davila-Velderrain
Jose Davila-Velderrain
LTLi-Huei Tsai
Li-Huei Tsai
Mef2 is induced after enrichment in mice, reduces disease-associated hyperexcitability, and is a feature of cognitive resilience in patients with AD.